Pancreatic Mixed Acinar-neuroendocrine-ductal Carcinoma: A Case Report and Literature Review

Ryohei Sakaguchi; Reiko Yamada; Kenji Nose; Takamitsu Tanaka; Yumi Murashima; Junya Tsuboi; Hayato Nakagawa

doi:10.2169/internalmedicine.1298-22

This article has now been updated. Please use the final version.

Pancreatic Mixed Acinar-neuroendocrine-ductal Carcinoma: A Case Report and Literature Review

Ryohei Sakaguchi, Reiko Yamada, Kenji Nose, Takamitsu Tanaka, Yumi Murashima, Junya Tsuboi, Hayato Nakagawa

Author information

Keywords: Mixed neuroendocrine-non-neuroendocrine neoplasm (MiNEN), Mixed acinar-neuroendocrine-ductal carcinoma, neuroendocrine carcinoma (NEC), acinar cell carcinoma (ACC), pancreatic ductal adenocarcinoma (PDAC), chemotherapy

JOURNAL OPEN ACCESS Advance online publication

Article ID: 1298-22

DOI https://doi.org/10.2169/internalmedicine.1298-22

The final version of this article is now available: Vol. 62 (2023), No. 22 pp. 3347-3353

Details

Abstract

Pancreatic mixed neoplasms are very rare. We herein report a unique case of pancreatic mixed acinar-neuroendocrine-ductal carcinoma with trilineage differentiation. The patient was an 83-year-old woman referred to our hospital due to anemia and a pancreatic mass. Contrast-enhanced computed tomography revealed a 60-mm mass in the pancreas. Subtotal stomach-preserving pancreaticoduodenectomy was performed. The postoperative pathological diagnosis was mixed acinar-neuroendocrine-ductal carcinoma. Postoperative chemotherapy was conducted according to the adenocarcinoma and neuroendocrine carcinoma protocols. The patient died 26 months postoperatively. Choosing appropriate chemotherapy for mixed neoplasms is difficult. Cancer gene panel testing, if possible, may support the choice of therapeutic agents.

Corresponding author

Register with J-STAGE for free!